

Prof. Dr. med. Khusru Asadullah

Publikationen

(chronologisch)

1994

1. Döcke WD, Syrbe U, Meinecke A, Platzer C, Makki A, **Asadullah K**, Klug C, Zuckermann H, Reinke P, Brunner H, von Baehr R, Volk HD (1994): Improvement of monocyte function - a new therapeutic approach ? In: Reinhart K, Eyrich K, Sprung C (Eds.) Sepsis - current perspectives in pathophysiology and therapy, Springer, Berlin Heidelberg New York, pp 473-500
2. Reinke P, Döcke WD, Syrbe U, Klug C, Zuckermann H, **Asadullah K**, von Baehr R, Volk HD (1994): Immunparalyse bei Sepsis - immunologische Analyse eines klinischen Phänomens; In: Vogt S, Metzner G, Haverich (Hrsg) *Immundiagnostik und Immuntherapie in der modernen Intensivmedizin*, Pabst Verlag, Lengrich, Berlin, Riga, Wien, Zagreb, pp 72-82

1995

3. **Asadullah K**, Woiciechowsky C, Liebenthal C, Döcke WD, Kox W, Volk HD, Vogel S, von Baehr R (1995): immunodepression following neurosurgical procedures; *Crit Care Med*, 23:1976-1983
(Impact factor: 6,283)
4. Volk HD, Reinke P, Krausch D, Zuckermann H, **Asadullah K**, Müller JM, Kox WJ, Döcke WD (1995): HLA-DR Expression auf Monozyten bei Peritonitis und Sepsis - Möglichkeiten eines therapeutischen Ansatzes. *Chir Gastroenterol*; 11 (suppl 2): 34-41
(Impact factor: 0,110)
5. **Asadullah K**, Woiciechowsky C, Döcke WD, Egerer K, Kox WJ, Vogel S, Sterry W, Volk HD, (1995): Very low monocytic HLA-DR Expression indicates high risk of infection - immunomonitoring for patients after neurosurgery and patients during high dose steroid therapy. *Eur J Emerg Med*, 2:184-190

1996

6. **Asadullah K**, Franze T, Dietze F (1996): Die Behandlung der Problematik Betreuung Sterbender im Medizinstudium - Ergebnisse einer Befragung von 565 Studenten und Ärzten; *Z Gerontol Geriat* 29:432-437
(Impact factor: 0,303)
7. Volk HD, Reinke P, Krausch D, Zuckermann H, **Asadullah K**, Müller JM, Kox WJ, Döcke WD (1996): Monocyte deactivation - rationale for a new therapeutic strategy in sepsis. *Intens Care Med*, 22:S474-S481
(Impact factor: 4,623)
8. **Asadullah K**, Haeußler A, Friedrich M, Siegling A, Olaizola-Horn S, Trefzer U, Volk HD, Sterry W (1996): IL-7 mRNA is not overexpressed in cutaneous T-cell lymphoma and is unlikely to be an autocrine growth factor in vivo. *Arch Derm Res*, 289:9-13
(Impact factor: 1,596)

9. **Asadullah K**, Döcke WD, Haeußler A, Volk HD, Sterry W, (1996): IFN γ and TNF α mRNA Expression in Mycosis fungoides progression. *Blood*, 88:757-758
(Impact factor: 10,896)
10. **Asadullah K**, Döcke WD, Haeußler A, Sterry W, Volk HD (1996): Progression of Mycosis fungoides is associated with increasing cutaneous expression of IL-10 mRNA, *J Invest Dermatol*, 107: 833-837
(Impact factor: 4,829)
11. **Asadullah K**, Schmid H, Döcke WD, Volk HD, Sterry W (1996): Wirkung von Monomethylfumarat (MMF) auf die Produktion von Zytokinen durch mononukleäre Zellen des peripheren Blutes (PBMC), In: Immunmodulation durch Fumadern (Symposiumsband), 16-20pp

1997

12. Woiciechowsky C, **Asadullah K**, Nestler D, Glöckner F, Robinson PN, Volk HD, Vogel S, Lanksch WR (1997): Release of cytokines into the cerebrospinal fluid following surgery for intra- and extra-axial brain tumors, *Acta Neurochir (Wien)*, 139:619-624
(Impact factor: 1,391)
13. **Asadullah K**, Döcke WD, Reinke P, Volk HD (1997): Zytokinbestimmungen - Diagnostischer Einsatz aus klinisch-immunologischer Sicht; *Deut Med Wochenschr*, 122:1424-1431
(Impact factor: 0,433)
14. Kox W, Bone RC, Krausch D, Döcke WD, Kox N, Wauer H, Egerer K, Querner S, **Asadullah K**, von Baehr, Volk HD (1997): Interferon- γ in the treatment of the compensatory anti-inflammatory response syndrome (CARS) - a new approach: proof of principle, *Arch Intern Med*, 157:389-393
(Impact factor: 8,391)
15. **Asadullah K**, Renz H, Döcke WD, Otterbach H, Wahn U, Köttgen E, Volk HD, Sterry W (1997): Verrucosis of hand and feet in a patient with combined immune deficiency, *J Am Acad Dermatol*, 36:850-852
(Impact factor: 2,904)
16. **Asadullah K**, Friedrich M, Döcke WD, Jahn S, Volk HD, Sterry W (1997): Enhanced expression of T-cell activation and natural killer cell antigens indicates systemic anti-tumor response in early primary cutaneous T-cell lymphoma (CTCL), *J Invest Dermatol*, 108:743-747
(Impact factor: 4,829)
17. Döcke WD, Reinke P, Syrbe U, Platzer C, **Asadullah K**, Krausch D, Zuckermann H, Volk HD (1997): Immunoparalysis in sepsis - from phenomenon to treatment strategies; *Transpl Med* 9:55-65
18. Muche M, Lukowsky A, **Asadullah K**, Gellrich S, Sterry W (1997): Demonstration of frequent occurrence of clonal T cells in the peripheral blood of patients with primary cutaneous T cell lymphoma, *Blood* 90: 1636-1642 (letter) (Impact factor: 10,896)

19. Döcke WD, Randow F, Syrbe U, Krausch D, **Asadullah K**, Reinke P, Volk HD, Kox W (1997): Monocyte deactivation in septic patients: restitution by IFN- γ treatment, *Nat Med*, 3:678-681
(Impact factor: 26,382)
20. **Asadullah K**, Schmid H, Friedrich M, Randow F, Volk HD, Sterry W, Döcke WD (1997): Influence of Monomethylfumarate on monocytic cytokine formation - explanation for adverse and therapeutic effects in psoriasis ? *Arch Derm Res*, 289:623-630
(Impact factor: 1,596)
21. **Asadullah K**, Döcke WD, Friedrich M, Haeußler A, Volk HD, Sterry W (1997): Granzyme A mRNA expression in mycosis fungoides progression, *Blood*, 90:3810-3811 (letter)
(Impact factor: 10,896)

1998

22. Jahn S, **Asadullah K**, Walden P, Sterry W (1998): Cutaneous malignant lymphomas, *Immunol Today*, 19:100-103
(Impact factor: 9,480)
23. **Asadullah K**, Sterry W, Stephanek K, Leupold M, Jasulaitis D, Audring H, Volk HD, Döcke WD (1998): IL-10 is a key cytokine in psoriasis: Proof of principle by IL-10 therapy - a new therapeutic approach, *J Clin Invest*, 101:783-794 (Impact factor: 16,915)
24. Woiciechowsky C, **Asadullah K**, Nestler D, Eberhardt B, Platzer C, Schöning B, Glöckner F, Lanksch WR, Volk HD, Döcke WD, (1998): Sympathetic activation triggers systemic interleukin-10 release in immunoderession induced by brain injury, *Nature Med*, 4:808-813
(Impact factor: 26,382)
25. Woiciechowsky C, **Asadullah K**, Nestler D, Schöning B, Glöckner F, Döcke WD Volk HD (1998): Diminished monocytic HLA-DR expression and ex vivo cytokine secretion capacity in patients with glioblastoma: Effect of tumor extirpation, *J Neuroimmunol* 84: 164-171
(Impact factor: 2,920)
26. **Asadullah K**, Döcke WD, Volk HD, Sterry W (1998): Cytokines and cutaneous T-cell lymphomas, *Exp Dermatol*, 7:314-320
(Impact factor: 2,951)

1999

27. **Asadullah K**, Döcke WD, Sabat R, Ebeling M, Volk HD, Sterry W, (1999): Interleukin-10 in der Dermatologie, *Hautarzt*, 50:12-19
(Impact factor: 0,333)
28. **Asadullah K**, Prösch S, Audring H, Volk HD, Sterry W, Döcke WD (1999): A high prevalence of cytomegalovirus antigenaemia in patients with moderate to severe psoriasis: an association with systemic TNF- α overexpression, *Br J Dermatol*. 1999 Jul;141:94-102.
(Impact factor: 3,503)

29. **Asadullah K**, Döcke WD, Ebeling M, Friedrich M, Belbe G, Audring H, Volk HD, Sterry W (1999): IL-10 treatment of psoriasis - clinical results of a Phase II trial, *Arch Dermatol*, 135: 187-192
(Impact factor: 2,845)
30. Arnold R, Seifert M, **Asadullah K**, Volk HD (1999): Crosstalk between keratinocytes and T-lymphocytes via Fas/Fas Ligand interaction: modulation by cytokines, *J Immunol*, 162:7140-7147
(Impact factor: 6,068)
31. **Asadullah K**, Muche M, Friedrich M, Sterry W (1999): Zirkulierende maligne und benigne Lymphozyten in Frühstadien kutaner Lymphome, in Plettenberg, Meigel, Moll (Hrsg). *Dermatologie an der Schwelle zum neuen Jahrtausend*, Springer, 463-466.
32. **Asadullah K**, Döcke WD, Volk HD, Sterry W (1999): Interleukin-10 als immunsuppressives Zytokin: Bedeutung für die Dermatologie, in Plettenberg, Meigel, Moll (Hrsg.) *Dermatologie an der Schwelle zum neuen Jahrtausend*, Springer, 13-16.
33. **Asadullah K**, Döcke WD, Volk HD, Sterry W (1999): The pathophysiological role of cytokines in psoriasis, *Drugs Today*, 35: 913-924
(Impact factor: 1,250)
34. **Asadullah K**, Sabat R, Wiese A, Döcke WD, Volk HD, Sterry W (1999): Interleukin-10 in cutaneous disorders: Implications for its pathophysiological importance and therapeutical use, *Arch Derm Res*, 291:628-636
(Impact factor: 1,596)

2000

35. **Asadullah K**, Gellrich S, Haeußler-Quade A, Friedrich M, Döcke WD, Jahn S, Sterry W (2000): Cytokine expression in primary cutaneous germinal center cell lymphomas, *Exp Dermatol*, 9:71-76
(Impact factor: 2,951)
36. Herzler M, Franze T, Dietze F, **Asadullah K** (2000): Dealing with the issue 'care of the dying' in medical education - results of a survey of 592 European physicians, *Med Educ*, 34:146-147
(Impact factor: 2,562)
37. **Asadullah K**, Döcke WD, Sabat R, Volk HD, Sterry W (2000): The treatment of psoriasis with interleukin-10: rationale and review of the first clinical trials, *Expert Opin Investig Drugs*, 9:95-102
(Impact factor: 3,667)
38. Seifert M, Sterry W, Effenberger E, Rexin A, Friedrich M, Haeußler-Quade A, Volk HD, **Asadullah K**, (2000): The antipsoriatic activity of IL-10 is rather caused by effects on peripheral blood cells than by direct effect on human keratinocytes, *Arch Derm Res*, 292:164-172
(Impact factor: 1,596)
39. **Asadullah K**, Haeußler-Quade A, Gellrich S, Döcke WD, Volk HD, Sterry W (2000): IL-15 and IL-16 overexpression in mycosis fungoides progression. *Exp Dermatol*, 9:248-251
(Impact factor: 2,951)

40. Rückert R, **Asadullah K**, Seifert M, VM Budagyan, Arnold R, Trombotto C, Paus R, Bulfone-Paus S (2000): Inhibition of keratinocyte apoptosis by IL-15: a new parameter in the pathogenesis of psoriasis. *J Immunol*, 165(4):2240-50 (Impact factor: 6,068)
41. Friedrich M, Krammig S, Henze M, Döcke WD, Sterry W, **Asadullah K** (2000): Flowcytometric characterisation of lesional T-cells in psoriasis: intracellular cytokine and surface antigen expression indicates a activated, memory/effector type 1 immunophenotype, *Arch Derm Res*, 292:519-521 (Impact factor: 1,596)

2001

42. Risch K, Strebel HP, Joshi RK, Lutz J, Brock J, **Asadullah K**, Volk H-D, Lehmann M (2001): Methyl hydrogen fumarate inhibits acute and chronic rejection in rat kidney transplantation models, *Transplant Proc*, 33:545-546 (Impact factor: 1,027)
43. **Asadullah K**, Eskdale J, Wiese A, Gallagher G, Friedrich M, Sterry W (2001): Interleukin-10 promotor polymorphism in psoriasis, *J Invest Dermatol*, 116:975-8. (Impact factor: 4,829)
44. **Asadullah K**, Friedrich M, Hanneken S, Rohrbach C, Audring H, Döcke WD, Vergopoulos A, Ebeling M, Volk HD, Sterry W (2001): Effects of systemic interleukin-10 therapy on psoriatic skin lesions: histological, immunohistological and molecularbiological findings, *J Invest Dermatol* 116:721-7 (Impact factor: 4,829)
45. **Asadullah K**, Döcke WD, Haeußler-Quade A, Sterry W, Volk HD (2001): Measurement of interleukins in cutaneous disorders. In: O'Neill and A. Bowie (Eds): *Methods in Molecular Medicine*, Vol 60: Interleukin Protocols, Humana Press Inc., Totowa, NJ, 239-250
46. Volk HD, **Asadullah K**, Gallagher G, Sabat R, Grütz G (2001): Interleukin-(IL)-10 and IL-10 homologs: an expanding family of important immune mediators and emerging immunotherapeutic agents. *Trends Immunol*, 22:414-417 (Impact factor: 9,480)
47. Gruenberg B.H., Schoenemeyer A., Weiss B., Toschi L., Wolk K., **Asadullah K**, Sabat R (2001): A novel, soluble homologue of IL-10 receptor with preferential expression in placenta. *Genes Immun*, 2(6):329-34. (Impact factor: 4,088)
48. Friedrich M, Klein A, Rückert R, Döcke WD, Sterry W, **Asadullah K** (2001): Addition of pentoxifylline could reduce the side effects of fumaric acid esters in treatment of psoriasis. *Acta Dermatol Venerol*, 81(6):429-30 (Impact factor: 1,927)

2002

49. Lehmann M, Risch K, Brock J, Lutz J, Volk HD, **Asadullah K** (2002): Fumaric acid esters are potent immunosuppressants: inhibition of acute and chronic rejection in rat kidney transplantation models by methyl hydrogen fumarate. *Arch Derm Res*, 294:399-404
(Impact factor: 1,596)
50. Friedrich M, Döcke WD, Klein A, Philipp S, Volk HD, Sterry W, **Asadullah K** (2002): Immunomodulation by IL-10 therapy decreases the incidence of relapse and prolongs the relapse-free interval in psoriasis. *J Invest Dermatol*, 118:672-677 (Impact factor: 4,829)
51. **Asadullah K**, Sterry W,: Experimentelle Therapien (2002) in: Psoriasis – auf einen Blick, Hrsg. Christophers, Mrowietz, Sterry, Blackwell-Verlag, Berlin, 125-140
52. Hennekes H, **Asadullah K** (2002): Strategies for targeting IL-4 as a novel therapeutic approach for the treatment of atopic dermatitis. *Curr Med Chem-AIAAD*, 1:41-53
53. **Asadullah K**, Volk HD, Sterry W: Novel immunotherapies for psoriasis (2002), *Trends Immunol*, 23:47-53
(Impact factor: 9,480)
54. Schäcke H, Hennekes H, Schottelius A, Jaroch S, Lehmann M, Schmees N, Rehwinkel H, **Asadullah K** (2002): Selective Glucocorticoid Receptor Agonists (SEGRAs): a novel class of anti-inflammatory compounds; In: *Proceedings of the ESRF workshop: Recent advances in GC-R Action*, (Eds.: Asadullah, Schaecke, Cato), Springer, Berlin, Heidelberg, 357-372pp
55. Sterry W, **Asadullah K** (2002): Topical glucocorticoid therapy in Dermatology. In: *Proceedings of the ESRF workshop: Recent advances in GC-R Action*, (Eds.: Asadullah, Schaecke, Cato), Springer, Berlin, Heidelberg, 39-54pp
56. **Asadullah K**, Sterry W, Volk HD (2002): Analysis of cytokine expression in dermatology, *Arch Derm*, 138:1-8
(Impact factor: 2,845)
57. **Asadullah K**, Sterry W, Trefzer U (2002): Cytokine therapy in dermatology, *Exp Dermatol.*, 2002:11:97-106
(Impact factor: 2,951)
58. Sabat R, **Asadullah K** (2002) Interleukin-10 in cancer immunity, In: *Cancer Immune Therapy: Experiences and Future Strategies* (Eds: G. Stuhler and P. Walden), Wiley-VCH, Weinheim
59. **Asadullah K**, Schäcke H, Cato A (2002): Dichotomy of glucocorticoid action in the immune system, *Trends Immunol*, 23,120-122
(Impact factor: 9,480)
60. Zügel U, Steinmeyer A, Giesen C, **Asadullah K** (2002): A novel 1alpha,25-Dihydroxyvitamin D3 analog with immunosuppressive activity at non-hypercalcemic dosages, *J Invest Dermatol*, 119:1434-42
(Impact factor: 4,829)
61. Schottelius AJ, Giesen C, **Asadullah K**, Fierro IM, Colgan SP, Baumann J, Guilford W, Perez HD, Parkinson JF (2002): An aspirin-triggered lipoxin A4 stable analog displays a unique topical anti-inflammatory profile. *J Immunol*: 169:7063-7070
(Impact factor: 6,068)

62. Wolk K, Kunz S, **Asadullah K**, Sabat R (2002): Immune cells as source and targets of the IL-10 family members? *J Immunol*, 168:5397-5402 (Impact factor: 6,068)
63. **Asadullah K**, Sterry W, Trefzer U (2002): Cytokines: Interleukin and Interferon therapy in dermatology; *Clin Exp Dermatol*, 27:578-584 (Impact factor: 1,522)
64. Schäcke H, Döcke WD, **Asadullah K** (2002): Mechanisms involved in the side effects of glucocorticoids, *Pharmacol Ther* 96:23-43. (Impact factor: 7.968)
65. **Asadullah K**, Volk HD, Friedrich M, Sterry W (2002): Experimental therapies for psoriasis *Archivum Immunologiae et Therapiae Experimentalis*, 50:411-420 (Impact factor: 1,689)

2003

66. Friedrich M, Sterry W, **Asadullah K** (2003): Novel developments in the systemic treatment of psoriasis. *JDDG*, 1:12-21
67. Döcke WD, Kiessling C, Worm M, Friedrich M, Pruss A, Weitz M, Prösch S, Kern F, Volk HD, Sterry W, **Asadullah K** (2003): Subclinical activation of latent cytomegalovirus (CMV) infection and anti-CMV immune response in patients with atopic dermatitis. *Br J Dermatol*. 148:954-63. (Impact factor: 3,503)
68. Schottelius A, Hamann A, **Asadullah K** (2003): Fucosyltransferases in leukocyte trafficking: major impact for cutaneous immunity, *Trends Immunol*, 24:101-4. (Impact factor: 9,480)
69. Friedrich M, Holzmann R, Sterry W, Wolk K, Truppel A, Piazena H, Sabat R, **Asadullah K** (2003): UV-B radiation-mediated inhibition of interferon-gamma induced keratinocyte activation is independent of IL-10 and other soluble mediators but associated with enhanced intracellular SOCS expression, *J Invest Dermatol.*;121:845-52. (Impact factor: 4,829)
70. Seifert M, Gruenberg BH, Sabat R, Donner P, Gruetz G, Volk HD, Wolk K, **Asadullah K** (2003): Keratinocyte unresponsiveness towards interleukin-10: lack of specific binding due to deficient IL-10 receptor 1 expression. *Exp Dermatol* 12:137-44. (Impact factor: 2,951)
71. Hensen P, **Asadullah K**, Windemuth C, Rüschemdorf F, Hüffmeier U, Ständer M, Schmitt-Egenolf M, Wienker TF, Reis A, Traupe H (2003): Interleukin-10 Promoter Polymorphism IL10.G and Familial Early Onset Psoriasis, *Br J Dermatol*, 149:381-385 (Impact factor: 3,503)
72. **Asadullah K**, Friedrich M, Döcke WD, Sabat R, Volk HD, Sterry W (2003): Interleukin-10 therapy - a new therapeutic approach for psoriasis, In: Bonnekoh B and Gollnick H (Eds): Clinical-experimental advances in dermatological diagnostics and treatment, Biblomed, Melsungen, pp97-104

73. **Asadullah K**, Sterry W, Trefzer U (2003): Interleukin- und Interferontherapie in der Dermatologie, *Zeitschrift für Hauterkrankungen*, 77:656-662
74. **Asadullah K**, Sterry W, Volk HD (2003): Interleukin-10 therapy - review of a new approach *Pharmacology Rev*, 55:241-69 (Impact factor: 18,823)
75. Trefzer U, Hofmann M, Sterry W, **Asadullah K** (2003): Cytokine and anti-cytokine therapy in dermatology, *Expert Opin Biol Ther*: 3:733-43. (Impact factor: 2,815)
76. Friedrich F, Philipp S, Sabat R, **Asadullah K**, Sterry W (2003): Einsatz von Biologicals bei Psoriasis in der Dermatologie, *Z Rheumtol* 62:439-449 (Impact factor: 0,651)
77. Zollner T, **Asadullah K** (2003): Interfering with Selectin – Selectin Ligand Binding: A Bittersweet Attraction, *J Clin Invest*, 112 980-983 (Impact factor: 16,915)

2004

78. Schäcke H, Schottelius A, Döcke WD, Strehlke P, Jaroch S, Schmees N, Rehwinkel H, Hennekes H, **Asadullah K** (2004): Dissociation of transactivation from transrepression by selective glucocorticoid receptor agonists leads to separation of therapeutic effects from side effects, *P Natl Acad Sci USA*, 101:227-232 (Impact factor: 9,598)
79. **Asadullah K**, Sabat R, Friedrich M, Volk HD, Sterry W (2004): Interleukin-10: an important immunoregulatory cytokine with major impact in psoriasis *Current Drug Targets – Inflammation and Allergy*, 2004, 3:185-192 (Impact factor: 4,035)
80. **Asadullah K**, Sterry W, Volk HD: Interleukin-10 and psoriasis, book chapter, in: Interleukin-10, Editor: F.M. Marincola, NIH, Eureka. Com. 2004, Landes Bioscience
81. Driessler F, Venstrom K, Sabat R, **Asadullah K**, Schottelius AJG: Molecular Mechanisms of Interleukin-10 mediated inhibition of NF- κ B activity: A Role for p50, *Clin Exp Immunol* 2004 , 135:64-73. (Impact factor: 2,599)
82. Jung M, Sabat R, Krätzschar J, Seidel H, Wolk K, Schönbein C, Schütt S, Friedrich M, Döcke WD, **Asadullah K**, Volk HD, Grütz G (2004): Expression profiling of IL-10 regulated genes in human monocytes and peripheral blood mononuclear cells from psoriatic patients during IL-10 therapy, *Eur J Immunol* 34:481-93. (Impact factor: 4,662)
83. Zollner TM, Renz H, Igney FH, **Asadullah K** (2004) Animal Models of T Cell Mediated Skin Diseases. *Bioessays*, 26:693-696, 2004 (Impact factor: 5,402)
84. Schottelius AJG, Moldawer L, Dinarello CA, **Asadullah K**, Sterry W, Edwards CK: Biology of Tumor Necrosis Factor α – Implications for Psoriasis, *Exp Dermatol* 2004, 1-34 (Impact factor: 2,951)
85. May E, **Asadullah K**, Zügel U: Immunoregulation through 1,25-(OH)₂-vitamin D₃ and its analogs; *Current Drug Targets Inflamm Allergy*, 2004:3:377-393

86. Cato AC, Schäcke H, Sterry W, **Asadullah K**: The Glucocorticoid receptor as target for classic and novel anti-inflammatory therapy; *Current Drug Targets Inflamm Allergy*, 2004;3:347-353
87. Wolk K, Kunz S, Witte E, Friedrich M, **Asadullah K**, Sabat R: IL-22 increases the innate immunity of tissues. *Immunity*. 2004 (2):241-54. (Impact factor: 19,266)
88. Weiss B, Wolk K, Grünberg BH, Volk HD, Sterry W, **Asadullah K**, Sabat R: Cloning of murine IL-22 receptor alpha 2 and comparison with its human counterpart, *Genes and Immunity*, 2004;5, 330-336 (Impact factor: 4,088)
89. **Asadullah K**, Metternich R (2004): Nuclear receptors: old targets, new opportunities; *Current Drug Targets Inflamm Allergy*, 2004;3:333-334
90. Igney FH, **Asadullah K**, Zollner TM (2004): Techniques: Species' finest blend – humanized mouse models in inflammatory skin disease research. *Trends Pharmacol Sci*, 25 (10), 543-549 (Impact factor: 9,610)
91. Zollner T, Igney FH, **Asadullah K** (2004): Acute and chronic models of allergic contact dermatitis: advantages and limitations. Book chapter in: Animal Models of T cell-mediated skin diseases; Editors Zollner T, Renz H, Asadullah K; Springer Berlin, Heidelberg, New York, ISBN: 3-540-21067-9, 255-275pp
92. **Asadullah K**, Döcke WD, Friedrich M, Volk HD, Sterry W: Zytokine und kutane Lymphome, *Akt Dermatol*, 2004: 30: 543-548

2005

93. Schottelius AJ, **Asadullah K**, Zollner TM: From Bench to Bedside: Bringing Understanding of Cutaneous T-cell Recruitment to Patients, book chapter In: Boehncke WH, Lymphocyte homing to the skin, CRC Press, Boca Raton, USA, 2005; 185-199pp
94. Mrowietz U, **Asadullah K**: Dimethylfumarate for psoriasis: more than a dietary curiosity. *Trends Mol Med*, 2005, 11:43-48 (Impact factor: 7,244)
95. Wolk K, Witte E, Reineke U, Witte K, Friedrich M, Sterry W, **Asadullah K**, Volk HD, Sabat R: Is there an interaction between interleukin-10 and interleukin-22 ? *Genes and Immunity*, 2005;6,8-18 (Impact factor: 4,088)
96. Schäcke H, Rehwinkel H, **Asadullah K**: Dissociated glucocorticoid receptor ligands: compounds with an improved therapeutic index. *Current Opinion in Investigational Drugs* 2005,6:503-507
97. Numerof RP, Dinarello CA, **Asadullah K**: Cytokines as potential therapeutic targets for inflammatory skin diseases. *Eur Cytokine Netw*. 2005;16(2):101-3. (Impact factor: 2,064)
98. **Asadullah K**, Sabat R, Friedrich M, Döcke WD, Volk HD, Sterry W (2006): Interleukin-10 therapy as a new therapeutic approach- update, *Journal Salud Ciencia*,

2006

99. Baier G, **Asadullah A**, Zügel U (2006) The Immunological Synapse: Kinases in T Cell Signalling as Potential Drug Targets, *Immunology Lett*, 2006;105(1):3-5. (IF 2,628)
100. Schäcke H, Rehwinkel H, **Asadullah K**, Cato A (2006): Insight into the molecular mechanisms of glucocorticoid receptor action promotes identification of novel ligands with an improved therapeutic index, *Exp Dermatol*, 15 (8):565-573 (Impact factor: 2,951)
101. Schoepe S, Schäcke H, May E, **Asadullah K** (2006) Glucocorticoid therapy induced skin atrophy, *Exp Dermatol*, 15(6):406-420. (Impact factor: 2,951)
102. Wolk K, Witte E, Wallace E, Doecke WD, Kunz S, **Asadullah K**, Volk HD, Sterry W, Sabat R: IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis, *Eur J Immunol*, 2006, 36 (5):1309-23. (Impact factor: 4,662)
103. **Asadullah K**, Sabat R (2006): Interleukin-10 family – old and new promising cytokines, (Editorial) *Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry*, 3 (5): 205-206
104. Sabat R, Wallace E, **Asadullah K**, Sterry W, Volk HD, Wolk K: Soluble receptors of the Interleukin-10 family of cytokines: Interleukin-22 receptor alpha 2. (2006) *Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry*, 3 (5): 215-221
105. **Asadullah K**, Sabat R, Friedrich M, Doecke WD, Volk HD, Sterry W: Interleukin-10 (2006). *Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry*, 3 (5): 223-231
106. Igney FH, **Asadullah K**, Zollner T (2006): Humanized mouse models in drug discovery for skin inflammation. *Exp Opin Drug Discov* 1(1): 53-68.
107. Numerof R, **Asadullah K** (2006): Cytokine and anti-cytokine therapies for psoriasis and atopic dermatitis, *BioDrugs*, 20(2)93-103 (Impact factor: 2,273)
108. **Asadullah K**, Sabat R, Friedrich M, Döcke WD, Volk HD, Sterry W (2006): Interleukin-10 therapy in dermatology, book chapter for *Cytokine and anti-cytokine therapy in Dermatology Eds.: Asadullah, Volk, Sterry*, ISBN: 81-7895-220-3, Transworld Research Network, Kerala, India, 2006, pp63-74
109. **Asadullah K**, Doecke WD, Sterry W, Volk HD (2006): Detection of Cytokine Expression in Dermatology; book chapter for *Cytokine and anti-cytokine therapy in Dermatology, Eds.: Asadullah, Volk, Sterry*, ISBN: 81-7895-220-3, Transworld Research Network, Kerala, India, 2006, pp13-24
110. **Asadullah K**, Numerof B, Sterry W, Volk HD (2006). Cytokines: Immunobiology of key mediators of dermatological homeostasis and disease, book chapter for *Cytokine and anti-cytokine therapy in Dermatology, Eds.: Asadullah, Volk, Sterry*, ISBN: 81-7895-220-3, Transworld Research Network, Kerala, India, 2006, pp1-12

111. Kunz S, Wolk K, Witte E, Witte K, Doecke WD, Volk HD, Sterry W, **Asadullah K**, Sabat R (2006): IL-19, IL-20, and IL-24 are produced by and act on keratinocytes and are distinct from classical interleukins. *Exp Dermatol*, 15:991-1004 (Impact factor: 2,951)
112. Schottelius A, **Asadullah K**, Sterry W (2006): Anti- TNF- α Therapy in Dermatology book chapter for *Cytokine and anti-cytokine therapy in Dermatology Eds.: Asadullah, Volk, Sterry*, ISBN: 81-7895-220-3, Transworld Research Network, Kerala, India, 2006, pp129-152
113. Bonin A, Buchmann B, Bader B, Rausch A, Venstrom K, Schäfer M, Gründemann S, Günther J, Zorn L, Nubbemeyer R, **Asadullah K**, Zollner TM (2006). Efomycin M: an inhibitor of selectins? *Nat Med*, 12 (8):873 (Impact factor: 26,382)
114. **Asadullah K**, Sterry W (2006): The molecular basis of psoriasis. *Encyclopedic Reference of Genomics and Proteomics*, 1579-1582pp, (kein IF); In *Springer Reference Ganten, Ruckpaul (Eds.)* ISBN 10-3-540-44244-8, Berlin, Heidelberg, New York,

2007

115. Zollner T, **Asadullah K**, Schoen M (2007): Targeting leukocyte trafficking to inflamed skin- still an attractive therapeutic approach, *Exp Dermatol* 16:1-12 (IF: 2,951)
116. Listopad J, **Asadullah K**, Sievers C, Ritter T, Meisel C, Sabat R, Döcke WD (2007): Heme oxygenase-1 inhibits T cell-dependent skin inflammation and function of antigen-presenting cells, *Exp Dermatol*, 16, 661-670 (Impact factor: 2,951)
117. Lehmann J, Listopad J, Hennekes H, **Asadullah K**, Docke WD (2007): Fumaric Acid Diesters induce Immunosuppression via Glutathione Depletion and subsequent Induction of Heme Oxygenase 1, *J Invest Dermatol*, 127(4):835-45. (Impact factor: 4,829)
118. **Asadullah K**, Gaestel M (2007): Protein kinase inhibitors for the treatment of inflammation- an overview. *Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry*, 6 (1): 3-4
119. **Asadullah K**, Gaestel M (2007): Kinase targets and inhibitors in inflammation. Editorial. *Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry*, 6 (1): 1
120. Mirshahpanah P, Doecke WD, Merbold U, **Asadullah K**, Roesel L, Schaecke H, Zollner T (2007): Superior nuclear receptor selectivity and therapeutic index of methylprednisolone aceponate versus mometasone furoate. *Exp Dermatol*, 9:753-6 (Impact factor: 2,951)
121. Gaestel M, Mengel A, Bothe U, **Asadullah K** (2007) Protein kinases as small molecule inhibitor targets in inflammation, *Curr Med Chem*, 14:2214-2234 (Impact factor: 4,944)
122. Schäcke H, Berger M, Rehwinkel H, **Asadullah K** (2007): Selective Glucocorticoid Receptor Agonists (SEGRAs): novel ligands with an improved therapeutic index. *Mol Cell Endocrinol*, 275:109-117 (Impact factor: 2,971)

123. Wolk K, Witte E, Hoffmann U, Doecke WD, Endesfelder S, **Asadullah K**, Sterry W, Volk HD, Wittig BM, Sabat R (2007): Interleukin-22 Induces Lipopolysaccharide Binding Protein in Hepatocytes: a Potential Systemic Role of Interleukin-22 in Crohn's Disease; *J Immunol* ;178(9):5973-81 (Impact factor: 6,068)
124. Sabat R, Philipp S, Höflich C, Kreutzer S, Wallace E, **Asadullah K**, Volk HD, Sterry W, Wolk K: Immunopathogenesis of psoriasis (2007). *Exp Dermatol*. 16:779-798 (IF: 2,951)
125. **Asadullah K**, Sterry W (2007): Gründung des Deutschen Hautforschungszentrums. *DDGJ, Editorial*, 5(12):1085-1086 (Impact factor: 1,471)

2008

126. Wolk K, Witte K, Witte E, Proesch S, Schulze-Tanzil G, Nasilowska, T, Thilo J, **Asadullah K**, Sterry W, Volk HD, Sabat R (2008): Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. *J Leukoc Biol.*;83(5):1181-93. (Impact factor: 4,128)
127. Mirshahpanah P, Li YY, Burkhardt N, **Asadullah K**, Zollner TM (2008): CCR4 and CCR10 ligands play additive roles in mouse contact hypersensitivity, *Exp Dermatol*, 17(1):30-34 (Impact factor: 2,951)
128. Schäcke H, **Asadullah K**, Döcke WD (2008): Side effects of topical and oral glucocorticoids. Book chapter in: *Overcoming steroid insensitivity in respiratory disease*. Editors: I.M. Adcock and K.F. Chung; J Wiley & Son Ltd. Chichester, England, ISBN: 978-0-470-05808-4. 19-38pp,
129. Schoenbein C, Doecke WD, Wolk K, Belbe G, Hoeflich C, Jung M, Gruetz G, Sterry W, Volk HD, **Asadullah K**, Sabat R (2008): Long-term IL-10 presence induces the development of a novel, monocyte derived cell type, *Clin Exp Immunol*, 151(2):306-316 (Impact factor: 2,599)
130. May E, Zollner T, Schäcke H, Schoepe S, Rehwinkel H, Sterry W, **Asadullah K** (2008): Glucocorticoids and atopic dermatitis. Book chapter in: *Textbook of Atopic Dermatitis*, Reitamo S, Luger T, and Steinhoff M (Series Eds), Series Title: Series in Dermatological Treatment, London, Informa Healthcare UK Ltd. London; 165-179pp
131. Gust TC, Neubrandt L, Merz C, **Asadullah K**, Zügel U, von Bonin A (2008): RNA interference-mediated gene silencing in murine T cells: in vitro and in vivo validation of proinflammatory target genes, *Cell Commun Signal*. 2008 Aug 6;6:3. (Impact factor: 5,500)
132. May E, Steinmeyer A, **Asadullah K**, Zügel U (2008): 11,25(OH)-Vitamin D3 and its dissociated Analogs as Modulators of Vitamin D Receptor Action. Book chapter in: *Nuclear receptors as drug targets*; Editors: Ottow E and Weinmann H. Wiley-VCH Verlag, Weinheim, Germany, ISBN: 978-3-527-31872-8; Book chapter, 325-366
133. Schäcke H, **Asadullah K**, Berger M, Rehwinkel H (2008): Novel Glucocorticoid Receptor Ligands. Book chapter in: *Nuclear receptors as drug targets*, Editors: Ottow E

and Weinmann H. Wiley-VCH Verlag, Weinheim, Germany, ISBN: 978-3-527-31872-8; Book chapter, 305-323

2009

134. Döcke WD, **Asadullah K**, Belbe G, Ebeling M, Höflich C, Friedrich M, Sterry W, Volk HD (2009): Comprehensive biomarker monitoring in cytokine therapy: heterogeneous, time-dependent, and persisting immune effects of Interleukin-10 application in psoriasis, *J Leukoc Biol* 85:582-593 (Impact factor: 4,128)
135. Schäcke H; Zollner TM, Döcke WD, Rehwinkel H, Jaroch S, Skuballa W, Neuhaus R, May E, Zügel U, **Asadullah K** (2009): A novel, selective glucocorticoid receptor agonist (SEGRA) for the topical therapy of inflammatory skin diseases: first report and pharmacological characterization of ZK 245186, *Br J Pharmacol*. 2009;158(4):1088-103. (Impact factor: 3,767)
136. Koch N, Jung M, Sabat R, Krätzschmar J, Döcke WD, **Asadullah K**, Volk HD, Grütz G (2009): IL-10 protects monocytes and macrophages from complement mediated lysis, *J Leukoc Biol*. 2009 Jul;86(1):155-66. (Impact factor: 4,128)
137. Zügel U, Steinmeyer A, May E, Lehmann M, **Asadullah K**, (2009): Immunomodulation by a Novel Dissociated Vitamin D Analogue, *Exp Dermatol*; 2009;18(7):619-27. (Impact factor: 2,951)
138. Wolk K, Witte E, Warszawska K, Schulze-Tanzil G, Witte K, Philipp S, Kunz S, Döcke WD, **Asadullah K**, Volk HD, Sterry W, Sabat R (2009): The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis; *Eur J Immunol*. 2009, 39(12):3570-81. (Impact factor: 5,103)
139. Witte K, Gruetz G, Volk HD, Looman AC, **Asadullah K**, Sterry W, Sabat R, Wolk K (2009): Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to the type III interferons: implications for therapeutic applications of these cytokines, *Genes Immun*. 2009, 10:702-714
140. Lucas JL, Mirshahpanah P, Haas-Stapleton E, **Asadullah K**, Zollner T, Numerof RP (2009): Induction of Foxp3⁺ Regulatory T Cells with Histone Deacetylase Inhibitors, *Cell Immunology*, 257: 97-104 (Impact factor: 1,808)

2010

141. Schottelius AJ, Zuegel U, Doecke WD, Zollner T, Mengel A, Buchmann B, Becker A, Gaestel M, **Asadullah K** (2010): The role of mitogen-activated protein kinase- activated protein kinase 2 in the p38/TNF- α pathway of systemic and cutaneous inflammation *J Invest Dermatol*, 2010, 130:481-491 (Impact factor: 6,314)
142. Schoepe S, Schäcke H, Bernd A, Zöller N, **Asadullah K**. (2010): Identification of Novel in vitro Test Systems for the Determination of Glucocorticoid Receptor Ligand-Induced Skin Atrophy. *Skin Pharmacol Physiol*. 2010;23(3):139-51 (Impact factor: 2,916)

2011

143. Lessl M, Bryans JS, Richards D, **Asadullah K** (2011): Crowd sourcing in drug discovery. *Nature Reviews Drug Discovery*, 2011; 10:241-242 (*Impact factor: 29,008*)
144. Lessl M, Schoepe S, Sommer A, Schneider M, **Asadullah K** (2011): Grants4targets- an innovative approach to translate ideas from basic research into novel drugs. *Drug Discov Today*. 2011, 16:288-292 (*Impact factor: 6,828*)
145. von Bonin A, Rausch A, Mengel A, Hitchcock M, Krüger M, von Ahsen O, Merz C, Röse L, Stock C, Martin SF, Leder G, Döcke WD, **Asadullah K**, Zügel U (2011). Inhibition of the IL-2-inducible tyrosine kinase (Itk) activity: a new concept for the therapy of inflammatory skin diseases. *Exp Dermatol.*, 2011;20(1):41-7. (*Impact factor: 3,543*)
146. **Asadullah K**, Kramer F (2011): Biomarkers for intensive care medicine patients: the (stony) path into a bright future? *J Biomarkers*, 2011; 16 Suppl 1:S1-4.
147. Weitz M, Kiessling C, Friedrich M, Prösch S, Höflich C, Kern F, Volk HD, Sterry W, **Asadullah K**, Döcke WD (2011): Persistent CMV infection correlates with disease activity and dominates the phenotype of peripheral CD8+ T cells in psoriasis, *Exp Dermatol*, 2011 Jul;20(7):561-7 (*Impact factor: 3,543*)
148. Swifka J, **Asadullah K**, Schmitz A (2011) Research Biobanking: need, socioethical considerations, and best practice. *Book chapter for Modern Biopharmaceuticals, Vol. 5 (Knaeblein, J, ed.) WILEY-VCH (2011) in press*
149. **Asadullah K**, Sterry W (2011). Vorwort und Vorstellung des Deutschen Hautforschungszentrums. *Fortschritte in der Psoriasis Forschung. ForMed.* 1: 8-10
150. MP Schön, K. Barthel, S. Jahn, **Asadullah K**, Zollner T (2011): Experimentelle Therapien der Psoriasis. *Fortschritte in der Psoriasis Forschung. ForMed.* 1: 40-48
151. Schoepe S, Schäcke H, **Asadullah K** (2011): Test systems for the determination of glucocorticoid receptor ligand induced skin atrophy. *Dermatoendocrinol* 2011 Jul;3(3):175-9.
152. Gross D, Schmitz AA, Vonk R, Igney FH, Döcke WD, Schoepe S, Sterry W, **Asadullah K** (2011) Willingness to donate human samples for establishing a dermatology Research Biobank: results of a survey. *Biopreservation and Biobanking*, 2011 Sep;9(3):265-271 (*Impact factor: 1,294*)
153. Schoepe S, Vonk R, Schäcke H, Zollner TM, **Asadullah K**, Röse L (2011): Shortened treatment duration of glucocorticoid induced skin atrophy in rats. *Exp Dermatol*; 2011 Oct;20(10):853-5. (*Impact factor: 3,543*)
154. Gashaw I, Ellinghaus P, Sommer A, **Asadullah K** (2011): What makes a good drug target? *Drug Discov Today*. 2011 Dec;16(23-24):1037-43. (*Impact factor: 6,828*)
155. Prinz F, Schlange T, **Asadullah K** (2011): Believe it nor not – how much can we rely on published data? *Nature Reviews Drug Discovery*, 10(9), 712 (*Impact factor: 29,008*)

2012

156. Landis SC, Amara SG, **Asadullah K**, Austin CP, Blumenstein R, Bradley EW, Crystal RG, Darnell RB, Ferrante RJ, Fillit H, Finkelstein R, Fisher M, Gendelman HE, Golub RM, Goudreau JL, Gross RA, Gubitza AK, Hesterlee SE, Howells DW, Huguenard J, Kelner K, Koroshetz W, Krainc D, Lazic SE, Levine MS, Macleod MR, McCall JM, Moxley RT 3rd, Narasimhan K, Noble LJ, Perrin S, Porter JD, Steward O, Unger E, Utz U, Silberberg SD (2012): A call for transparent reporting to optimize the predictive value of preclinical research. *Nature*. 2012 Oct 11;490(7419):187-91 (*Impact factor: 42,351*)

2014

157. Witte E, Kokolakis G, Witte K, Philipp S, Doecke WD, Babel N, Wittig BM, Warszawska K, Kurek A, Erdmann-Keding M, Kunz S, **Asadullah K**, Kadin ME, Volk HD, Sterry W, Wolk K, Sabat R (2014): IL-19 is a component of the pathogenetic IL-23/IL-17 cascade in psoriasis, *J Invest Dermatol*, 2014 Nov; 134(11):2757-67
158. Lessl M, **Asadullah K** (2014): Collaborative innovation in pharmaceutical industry: approaches and requirements. Book chapter in “*Collaborative Innovation in Drug Discovery*” Editor: Chaguturu R, 255-266pp, Wiley, 2014

2015

159. Dorsch H, Jurock AE, Schoepe S, Lessl M, **Asadullah K** (2014): Grants4Targets – an open innovation initiative to foster drug discovery collaborations between academia and the pharmaceutical industry, *Nature Reviews Drug Discovery*, 2015 Jan;14(1): 74-76 (*Impact factor: 37,231*)
160. von Lanzanauer SH, Wolk K, Höflich C, Kunz S, Grünberg BH, Döcke WD, Reineke U, **Asadullah K**, Sterry W, Volk HD, Sabat R (2015): Interleukin-10 receptor-1 expression in monocyte-derived antigen-presenting cell populations: dendritic cells partially escape from IL-10's inhibitory mechanisms, *Genes Immun*. 2015 Jan-Feb;16(1):8-14.
161. Schmitz AA, Hackethal S, Schulz A, May E, Steinmeyer A, Zügel U, **Asadullah K** (2015): Pharma compound sharing with academia: experiences with providing Vitamin D Receptor ligands, *Nature Reviews Drug Discovery*. 2015 (14): 294-296. (*Impact factor: 37,231*)
162. **Asadullah K**, Busch A, Gottwald M, Reinke P, Landeck L: Industry-academia collaborations for biomarkers. *Nat Rev Drug Discov*. 2015 Dec;14(12):805-6. (*Impact factor: 37,231*)

2016

163. Landeck L, Holland RL, **Asadullah K**: Advances in precision medicine — time for a new journal. *Advances in Precision Medicine* vol.1(1):1–3.

- 164.Landeck L, Lessl M, Reischl J, Busch A, Carrigan P, Gottwald M, Petra Reinke, **Asadullah K**, Collaboration for success: the value of strategic collaborations for precision medicine and biomarker discovery. *Advances in Precision Medicine*, vol.1(1): 25–33.
- 165.Landeck L, Kneip C, Reischl J, **Asadullah K**. (2016): Biomarkers and personalized medicine: current status and further perspectives with special focus on dermatology. *Exp Dermatol*. 2016 May;25(5):333-9. doi: 10.1111/exd.12948. Review.

2018

- 166.Landeck L, **Asadullah K**, Amasuno A, Pau-Charles I, Mrowietz U. (2018): Dimethyl fumarate (DMF) vs. monoethyl fumarate (MEF) salts for the treatment of plaque psoriasis: a review of clinical data. *Arch Dermatol Res*. 2018 Aug;310(6):475-483. doi: 10.1007/s00403-018-1825-9. Epub 2018 Mar 24. Review.

2020

- 167.Lauffer F, Eyerich K, Boehncke WH, **Asadullah K**, Beissert S, Ghoreschi K, Schön MP.: Zytokine der IL-17-Familie bei der Psoriasis. *J Dtsch Dermatol Ges*. 2020 Jul;18(7):675-681. doi: 10.1111/ddg.14124_g. Review

Dargestellte Impact Faktoren wurden zu unterschiedlichen Zeitpunkten erhoben/ sind nicht aktuell

Editions of books and special journal issues:

- Recent advances in Glucocorticoid-Receptor Action, Editors: **Asadullah K**, Schaecke H, Cato A; Springer Berlin, Heidelberg, New York, ISBN 3-540-43229-9, 2002
- Leukocyte trafficking: The role of fucosyltransferases and selectins. Editors: Hamann A, **Asadullah K**, Schottelius A; Springer Berlin, Heidelberg, New York, ISBN: 3-540-40112-1, 2004
- Nuclear receptors as anti-inflammatory drug targets: new opportunities, Editor: **Asadullah K**, Hot topic issue of *Current Drug Targets - Inflammation and Allergy*. 2004, Vol 3,
- Animal Models of T cell-mediated skin diseases, Editors: Zollner T, Renz H, **Asadullah K**, Springer Berlin, Heidelberg, New York, ISBN: 3-540-21067-9, 2005
- Cytokines as potential therapeutic targets for inflammatory skin diseases, Editors: Numerof R, Dinarello CA, **Asadullah K**, Springer Berlin, Heidelberg, New York, ISBN: 10 3-540-25427-7, 2005
- Cytokine and anti-cytokine therapy in Dermatology, Editors: **Asadullah K**, Volk HD, Sterry W, 2007, Transworld Research Network, Kerala, India, 2007
- Interleukin-10 Family - Old and New Promising Cytokines, Editors: **Asadullah K**, Sabat, R, Hot topic issue of *Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry* 2006, No. 3, Vol 5
- Kinase targets and inhibitors in inflammation. Editors: **Asadullah K**, Gaestel M, Hot topic issue of *Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry* 2007, 6 (1)
- Immunotherapy in 2020. Visions and trends for targeting inflammatory disease. Editors: Radbruch A, Volk HD, **Asadullah K**, Doecke WD. Springer Berlin, Heidelberg, New York, ISBN: 978-3-540-70850-6
- Fortschritte in der Psoriasis Forschung. Editors: **Asadullah K**, Sterry W (2011): *ForMed. Vol 1*.2011, ISSN 2191-9003, Alpha Informationsgesellschaft mbH, Lampertheim
- Biomarkers in intensive Care Medicine. Editors: **Asadullah K**, Kramer F (2011): Hot topic Issue. *Biomarkers*, 2011; 16 (S1); ISSN: 1354-750X